What are the guideline recommendations for diagnosing and managing diffuse parenchymal lung disease, including idiopathic pulmonary fibrosis (IPF) and connective‑tissue‑disease‑associated interstitial lung disease (CTD‑ILD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Guideline Recommendations for Diagnosing and Managing Diffuse Parenchymal Lung Disease

DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS

Initial Exclusion Criteria (Mandatory)

Take a detailed history of medication use and environmental exposures at home, work, and all frequently visited locations to exclude potential ILD causes 1, 2. Perform serological testing to exclude connective tissue diseases as a potential cause of the ILD 1, 2. This is non-negotiable before proceeding with IPF diagnosis.

Pulmonary Function Testing

Measure FVC and DLCO in all patients being evaluated for IPF 2. Additionally assess:

  • Total lung capacity
  • Resting arterial blood gas at room air
  • 6-minute walk test distance and percutaneous oxygen saturation 2

These tests show characteristic patterns: restrictive physiology (decreased FVC and total lung capacity), early DLCO decrease, and usually normal or hypocapnic arterial blood gases at rest 2.

High-Resolution Computed Tomography (HRCT)

HRCT showing a definite UIP pattern with honeycombing is sufficient to establish IPF diagnosis if other ILD causes have been excluded 2.

Definite UIP Pattern Requires ALL Four Features:

  • Subpleural basal predominance
  • Reticular abnormality
  • Honeycombing (clustered, thick-walled cystic spaces 3-10mm, up to 2.5cm) with or without traction bronchiectasis
  • Absence of features inconsistent with UIP 2, 3

Probable UIP Pattern (2018 refinement):

  • Subpleural basal predominance
  • Reticular abnormality with traction bronchiectasis
  • Absence of features inconsistent with UIP
  • No honeycombing 1

This occurs in approximately 50% of cases; the remaining require further evaluation 2.

Surgical Lung Biopsy

Perform video-assisted surgical lung biopsy when HRCT does not show a definite UIP pattern (conditional recommendation) 1, 2. However, do NOT perform surgical lung biopsy when HRCT shows definite UIP pattern (strong recommendation) 1.

The biopsy decision requires multidisciplinary discussion with careful evaluation of:

  • Patient age
  • Comorbidities
  • Disease severity and progression
  • Operative risk 2

Transbronchial Lung Cryobiopsy (TBLC)

The 2022 ATS/ERS/JRS/ALAT guideline suggests TBLC as an acceptable alternative to surgical lung biopsy for histopathological diagnosis in patients with ILD of undetermined type 4. The 2018 guideline made no recommendation either for or against cryobiopsy 1.

Key limitation: TBLC more commonly demonstrates probable UIP rather than definite UIP due to limited subpleural sampling, but combining UIP and probable UIP patterns in multidisciplinary discussion yields comparable diagnostic agreement to surgical biopsy 4.

Bronchoscopy Procedures NOT Recommended

Do NOT perform transbronchial lung biopsy (strong recommendation) - should not be used in IPF evaluation in the majority of patients 1.

Do NOT perform BAL cellular analysis in the majority of IPF patients (conditional recommendation against) 1. Exception: BAL may be appropriate when diagnostic overlap includes IPF/NSIP, IPF/hypersensitivity pneumonitis, or IPF/sarcoidosis, specifically to identify lymphocytosis >30% suggesting alternative diagnoses 3.

Serum Biomarkers

Do NOT measure serum MMP-7, SPD, CCL-18, or KL-6 for distinguishing IPF from other ILDs (strong recommendation) 1. Note: LDH and KL-6 remain sensitive for ILD detection and activity monitoring in clinical practice 5.

Multidisciplinary Discussion (MDD)

Conduct multidisciplinary discussion involving pulmonologists, radiologists, and pathologists experienced in interstitial pneumonias for definitive IPF diagnosis 1, 2. The definite diagnosis integrates clinical assessment, CT features, and when available, pathological features 2.

Refer complex cases to expert centers (reference or competence centers) or pulmonology departments experienced in ILDs 2.


PROGNOSIS ASSESSMENT IN IPF

At Diagnosis, Assess:

  • Severity of dyspnea
  • FVC and DLCO results
  • Percutaneous oxygen saturation at end of 6MWT
  • Extent of honeycombing on HRCT
  • Signs of pulmonary hypertension at echocardiography
  • GAP score (gender, age, physiology) for 1-, 2-, and 3-year survival estimates 2

During Follow-up, Monitor:

  • Progression of symptoms
  • >5% absolute or 10% relative decrease in FVC over 6 months (associated with ~2-fold mortality increase) 2, 6
  • >15% absolute or relative decrease in DLCO over 6 months
  • 50m decrease in 6MWT distance

  • Worsening fibrosis on HRCT
  • Signs of pulmonary hypertension 2

Poor prognostic factors include: older age, male sex, severe dyspnea, DLCO <35-40% predicted, oxygen saturation <88% during 6MWT at room air, extensive honeycombing, and pulmonary hypertension 2.


MANAGEMENT OF IPF

Antifibrotic Therapy

Do NOT initiate triple therapy with prednisone, azathioprine, and N-acetylcysteine in patients with definite IPF 2.

Initiate antifibrotic therapy with nintedanib or pirfenidone as soon as possible after diagnosis 6, 7, 8. These drugs:

  • Slow annual FVC decline by approximately 44-57%
  • Prevent acute exacerbations
  • Should be continued as long-term therapy 5, 6, 8

Consider switching to alternative antifibrotic drug if intolerance or significant progression occurs despite treatment 8. Do NOT combine both antifibrotic therapies 8.

Non-Pharmacological Management

Structured exercise therapy/pulmonary rehabilitation reduces symptoms and improves 6-minute walk test distance in individuals with dyspnea 6, 9.

Oxygen therapy reduces symptoms and improves quality of life in individuals who desaturate below 88% on 6-minute walk test 6.

Advanced Disease Management

Consider lung transplantation for patients with end-stage ILD 6. Post-transplant median survival is 5.2-6.7 years compared to <2 years without transplant in advanced disease 6.

For pulmonary hypertension (develops in up to 85% of end-stage fibrotic ILD): treatment with inhaled treprostinil improves walking distance and respiratory symptoms 6, 10.


CONNECTIVE TISSUE DISEASE-ASSOCIATED ILD (CTD-ILD)

Screening and Diagnosis

Perform baseline HRCT screening in systemic sclerosis due to high ILD prevalence 11. For other CTDs, screening recommendations vary but risk-based approaches are emerging.

For rheumatoid arthritis-associated ILD (RA-ILD), use validated risk scores incorporating:

  • Age at RA onset
  • DAS28-ESR disease activity scores
  • Sex
  • Optional: MUC5B rs35705950 genetic testing 11

Highest risk: males >58 years with DAS28-ESR >4.3 (87.2% risk of subclinical RA-ILD) 11.

Radiological Patterns

Most common CTD-ILD patterns:

  • UIP pattern: particularly in RA (associated with poorer survival similar to IPF)
  • NSIP pattern: most other CTDs including inflammatory myopathies
  • Organizing pneumonia: various CTDs 11, 6

NSIP shows more ground-glass opacities with or without reticulations; UIP shows more reticulation, bronchiectasis, and honeycombing 11.

Treatment

For CTD-ILD, use immunomodulatory therapy:

  • Mycophenolate mofetil (first-line for most CTD-ILD)
  • Tocilizumab
  • Rituximab 6, 9

These may slow decline or improve FVC at 12-month follow-up 6.

For progressive fibrosing CTD-ILD: antifibrotic therapy (nintedanib or pirfenidone) slows FVC decline, particularly in scleroderma-associated ILD 6, 10.

Monitoring

Follow high-risk patients even with normal baseline HRCT for new respiratory symptoms and monitor pulmonary function 11. In resource-limited settings, chest ultrasound can supplement chest examination 11.

Multidisciplinary collaboration between rheumatologists, pulmonologists, and radiologists is essential for accurate diagnosis and management 11, 12.


CRITICAL PITFALLS TO AVOID

  1. Do not diagnose IPF without excluding medication exposures, environmental exposures, and connective tissue disease - this is the most common diagnostic error 1, 2.

  2. Do not rely on transbronchial biopsy for IPF diagnosis - insufficient tissue sampling leads to misdiagnosis 1.

  3. Do not misinterpret traction bronchiectasis as honeycombing - honeycombing requires clustered thick-walled cystic spaces, not just dilated airways 2, 4.

  4. Do not perform surgical biopsy when HRCT shows definite UIP pattern - unnecessary risk without diagnostic benefit 1, 2.

  5. Do not use triple immunosuppressive therapy (prednisone/azathioprine/NAC) in IPF - associated with harm 2.

  6. Do not delay antifibrotic therapy once IPF is diagnosed - early treatment initiation is associated with better outcomes 5, 6, 8.

  7. Do not assume subclinical HRCT findings will progress - particularly in CTD-ILD, not all radiological abnormalities become clinically significant 11.

References

Guideline

diagnosis of idiopathic pulmonary fibrosis. an official ats/ers/jrs/alat clinical practice guideline.

American Journal of Respiratory and Critical Care Medicine, 2018

Research

[Diagnosis and Treatment of Interstitial Lung Diseases].

Deutsche medizinische Wochenschrift (1946), 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.